Treatment Horizons

Treatment Horizons by Chael Needle Surpassing Expectations ViiV Healthcare introduces its first FDA-approved agent ViiV Healthcare is exclusively devoted to the treatment of HIV disease, and the...

Undetectable is a worthy goal, no doubt about it. A suppressed viral load very often means the individual living with HIV is adherent to...

LifeGuide Heart Break in Melbourne Cardiovascular disease studies focus on assessment, management & treatment by Jeannie Wraight Cardiovascular disease (CVD) has become a leading cause of illness and...

On November 21, 2017, the U.S. Food and Drug Administration (FDA) approved the first-ever two-drug once-daily single-pill regimen for the maintenance treatment of adults...

A treatment for advanced HIV-associated Kaposi’s sarcoma is relaunched by Chael Needle Newly acquired by Galen from Gilead Sciences, DaunoXome (daunorubicin citrate liposome injection) is an...

NAPWA helps to promote immune-based therapies by Chael Needle At the International AIDS Conference last June, the AIDS Institute and the National Association of People with AIDS...

ViiV’s Dolutegravir Dual Therapy Works for Both First-Line & Maintenance Treatment Findings from the GEMINI and TANGO studies, reported at the 10th International AIDS Society...

Therapeutic Vaccine Research Toward a Functional Cure Shows Promise by Jeannie Wraight Until recently, therapeutic vaccines and immune-based therapies (IBTs) were all but shunned by the...

On July 26, 2017, the Centers for Disease Control and Prevention released new data on the nation’s progress in HIV testing and treatment, showing...

LifeGuide Running Into Options An NNRTI candidate seeks to keep on track to expand therapies by Chael Needle In this next-generation era of anti-HIV meds, research and development...